New York, USA – December 30, 2020 – Since the U.S. Food and Drug Administration (FDA) approved two CAR-T therapies targeting CD19 antigen in 2017 for the treatment of B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), CAR-T cell therapy, using genetic engineering to transform patients’ own T cells, and turn them into missiles against cancer, has become one of the hottest topics in cancer treatments.
With more than a decade of exploration and expansion, Creative Biolabs has optimized its one-stop CAR-T discovery services, including a variety of modules of cellular and gene therapy discovery services, covering T cell receptor T cell therapy, chimeric antigen receptor (CAR) T cell therapy, CAR NK cell therapy, CAR macrophage cell therapy, TCR identification, scGV generation and optimization, etc.
• Chimeric Antigen Receptor (CAR) T Cell Therapy
CAR-T therapy has shown its great potential in killing tumor cells for a long time. To accelerate the development of CAR-T based approaches, Creative Biolabs offers an end-to-end solution covering all steps prior to clinical trials for global clients.
The complete portfolio of CAR-T therapy development services includes but is not limited to neoantigen identification, scFV generation, CAR design and construction, CAR-T preparation, in vitro validation and in vivo testing.
• T Cell Receptor(TCR) T Cell Therapy
In clinical trials, TCR-T cell therapies have also produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. Supported by state-of-the-art technical platforms, expert teams at Creative Biolabs is confident to offer flexible solutions related to TCR-T cell therapy.
To develop TCR-T based approaches, Creative Biolabs offers streamlined end-to-end TCR-T services covering tumor-specific TCR identification, tumor-specific TCR generation and optimization, TCR design and construction, TCR-T preparation, in vitro validation and in vivo testing. Scientists at Creative Biolabs promise easier project management and less time to market.
Creative Biolabs is dedicated to custom services and products related to a full spectrum of targets in the immune system, such as T cell, B cell, NK cell, DC and macrophage. Besides, various bioassays, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) testing, immunoassay, FcR binding assay, immune cells function assay, immuno-oncology assay, etc.
More information can be found on https://www.creative-biolabs.com/immuno-oncology.
About Creative Biolabs
With a great passion for the new chapter of cancer treatment, Creative Biolabs believes that next-generation immunotherapy will provide the best opportunity to discover and advance the drug pipeline for global partners. The expert team now introduces the first-class therapeutic antibody and protein platforms to guide clients through challenges from target selection to IND regulatory support.